Phase Ib trial of ianalumab plus ibrutinib for CLL

(4:43)

A Phase IB Study FOLFIRINOX and NIS793 in Patients with Pancreatic Cancer

(3:39)

Update on Phase Ib trial of AVID200 in myelofibrosis

(3:2)

Phase Ib trial results on TLS density pre- and post-oncolytic immunotherapy with ICIs for MIBC

(3:44)

Long-term results of a Phase Ib trial of Isa-VRd in newly diagnosed transplant-ineligible myeloma

(1:53)

A phase Ib single-arm study of bintrafusp alfa

(5:50)

Results of a Phase Ib study of ibrutinib + obinutuzumab in R/R CLL

(2:58)

Phase Ib/II trial of 177Lu-girentuximab, cabozantinib and nivolumab in aRCC

(1:11)

Phase Ib Polatuzumab Vedotin Trial

(4:25)

[9] Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib-

(3:)

Phase Ib trial of acalabrutinib + rituximab with or without lenalidomide in R/R follicular lymphoma

(2:22)

Phase Ib trial of AVID200 in refractory myelofibrosis

(4:15)

Phase Ib trial of ianalumab and ibrutinib in CLL

(3:51)

The results of a Phase Ib/II study of CPX-351 plus venetoclax in patients with R/R AML

(2:43)

Phase Ib/II trial of 177Lu-girentuximab with cabozantinib and nivolumab in clear cell RCC

(54)

Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma

(45)

Phase Ib study of Orca-T in patients with advanced hematologic malignancies

(4:26)

A Phase Ib study of PRT503, a PRMT5 inhibitor, in R/R splicing factor-mutated myeloid malignancies

(3:16)